Eli Lilly’s once-weekly insulin efsitora alfa matches daily insulin for A1C reduction, boosts stock interest

Eli Lilly and Company (NYSE: LLY) announced results from its QWINT-5 phase 3 trial, demonstrating that its once-weekly insulin efsitora alfa offers a comparable reduction ... Read More